--- schema_version: "secwatch.filing_event.v1" accession: "0001193125-23-154191" form_type: "8-K" ticker: "KPTI" cik: "0001503802" company_name: "Karyopharm Therapeutics Inc." filed_at: "2023-05-25T23:59:59+00:00" generated_at: "2026-06-14T14:28:01.170588+00:00" event_type: "other_material" sentiment: "neutral" materiality_score: 0.5 calibrated_materiality_score: 0.5 confidence: "high" source: SEC EDGAR --- # KPTI shareholders approve doubling authorized shares to 400M, equity plan increases ## Summary - Authorized shares doubled from 200M to 400M after shareholder approval at the May 24, 2023 annual meeting. - Stockholders approved adding 5M new shares to the 2022 Equity Incentive Plan for future awards. - Amended ESPP increases share reserve from ~2.5M to ~4M and removes the evergreen provision. - Officer exculpation amendment approved, limiting officer liability for certain breach of fiduciary duty claims. ## SEC filing metadata - accession: 0001193125-23-154191 - form_type: 8-K - ticker: KPTI - cik: 0001503802 - company_name: Karyopharm Therapeutics Inc. - filed_at: 2023-05-25T23:59:59+00:00 - event_type: other_material - sentiment: neutral - materiality_score: 0.5 - calibrated_materiality_score: 0.5 - confidence: high - sec_items: 5.02, 5.07, 9.01 - EDGAR index: https://www.sec.gov/Archives/edgar/data/1503802/000119312523154191/0001193125-23-154191-index.htm - EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1503802/000119312523154191/d512308d8k.htm ## Machine-readable alternates - HTML: https://secwatch.observer/filing/0001193125-23-154191 - JSON: https://secwatch.observer/filing/0001193125-23-154191.json - Plain text: https://secwatch.observer/filing/0001193125-23-154191.txt ## Key facts - Shareholder Votes Karyopharm Therapeutics Inc. shareholders approved Approval of the Amended and Restated ESPP. - Proposal: equity plan - Outcome: passed source text: 3. The Company’s stockholders approved the Amended and Restated ESPP. evidence_url: https://www.sec.gov/Archives/edgar/data/1503802/000119312523154191/0001193125-23-154191-index.htm - Shareholder Votes Karyopharm Therapeutics Inc. shareholders approved Approval of an amendment to the Restated Certificate of Incorporation to increase authorized common stock from 200,000,000 to 400,000,000 shares (Share Increase Amendment). - Proposal: charter amendment - Outcome: passed source text: 4. The Company’s stockholders approved an amendment to the Company’s Restated Certificate of Incorporation, as amended, to increase the number of authorized shares of the Company’s common stock from 200,000,000 to 400,000,000 (the “Share Increase Amendment”). evidence_url: https://www.sec.gov/Archives/edgar/data/1503802/000119312523154191/0001193125-23-154191-index.htm - Shareholder Votes Karyopharm Therapeutics Inc. shareholders approved Approval of 2022 Plan Amendment to increase shares available for issuance under the 2022 Plan by 5,000,000 shares. - Proposal: equity plan - Outcome: passed source text: 2. The Company’s stockholders approved the 2022 Plan Amendment to increase the number of shares of the Company’s common stock available for issuance under the 2022 Plan by 5,000,000 shares. evidence_url: https://www.sec.gov/Archives/edgar/data/1503802/000119312523154191/0001193125-23-154191-index.htm - Shareholder Votes Karyopharm Therapeutics Inc. shareholders approved Election of Barry E. Greene, Mansoor Raza Mirza M.D. and Christy J. Oliger as Class I directors. - Proposal: director election - Outcome: passed source text: 1. The Company’s stockholders elected Barry E. Greene, Mansoor Raza Mirza M.D. and Christy J. Oliger as Class I directors, each to serve on the Board for a three-year term until the 2026 annual meeting of stockholders and until his or her resignation or removal or until his or her successor is duly elected and qualified. evidence_url: https://www.sec.gov/Archives/edgar/data/1503802/000119312523154191/0001193125-23-154191-index.htm - Shareholder Votes Karyopharm Therapeutics Inc. shareholders approved Advisory vote on the compensation of the Company's named executive officers as disclosed in the Proxy Statement. - Proposal: say on pay - Outcome: passed source text: 6. The Company’s stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers as disclosed in the Proxy Statement. evidence_url: https://www.sec.gov/Archives/edgar/data/1503802/000119312523154191/0001193125-23-154191-index.htm - Shareholder Votes Karyopharm Therapeutics Inc. shareholders approved Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023 at the 2023-12-31 meeting. - Proposal: auditor ratification - Outcome: passed - Meeting: 2023-12-31 source text: 7. The Company’s stockholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023. evidence_url: https://www.sec.gov/Archives/edgar/data/1503802/000119312523154191/0001193125-23-154191-index.htm - Shareholder Votes Karyopharm Therapeutics Inc. shareholders approved Approval of an amendment to the Restated Certificate of Incorporation to reflect new Delaware law provisions regarding officer exculpation (Officer Exculpation Amendment). - Proposal: charter amendment - Outcome: passed source text: 5. The Company’s stockholders approved an amendment to the Company’s Restated Certificate of Incorporation, as amended, to reflect new Delaware law provisions regarding officer exculpation (the “Officer Exculpation Amendment”). evidence_url: https://www.sec.gov/Archives/edgar/data/1503802/000119312523154191/0001193125-23-154191-index.htm This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.